Hypertrophic cardiomyopathy

Murillo de Oliveira Antunes; Thiago Luis Scudeler

doi:10.1016/j.ijcha.2020.100503

Hypertrophic cardiomyopathy

Int J Cardiol Heart Vasc. 2020 Mar 25:27:100503. doi: 10.1016/j.ijcha.2020.100503. eCollection 2020 Apr.

Authors

Murillo de Oliveira Antunes^{1

2}, Thiago Luis Scudeler¹

Affiliations

¹ Instituto do Coração (InCor), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
² Universidade São Francisco (USF), Bragança Paulista, São Paulo, Brazil.

Abstract

Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease. The disease is characterized by marked variability in morphological expression and natural history, ranging from asymptomatic to heart failure or sudden cardiac death. Left ventricular hypertrophy and abnormal ventricular configuration result in dynamic left ventricular outflow obstruction in most patients. The goal of pharmacological therapy in HCM is to alleviate the symptoms, and it includes pharmacotherapies and septal reduction therapies. In this review, we summarize the relevant clinical issues and treatment options of HCM.

Keywords: CMR, cardiac magnetic resonance; HCM, hypertrophic cardiomyopathy; HF, heart failure; ISH, interventricular septal hypertrophy; LVH, left ventricular hypertrophy; LVOT, left ventricular outflow tract; SAM, systolic anterior motion; SCD, sudden cardiac death.

Publication types

Review